Combination of Docetaxel + Estramustine + Hydrocortisone Versus Docetaxel + Prednisone in Patients With Advanced Prostate Cancer

Combination of Docetaxel + Estramustine + Hydrocortisone Versus Docetaxel + Prednisone in Patients With Advanced Prostate Cancer Who Have Relapse in Biochemistry Whilst Androgenic Blockage

To compare the efficacy of both strategies (reference treatment: Docetaxel+Prednisone and experimental treatment: Docetaxel+Estramustine+Hydrocortisone) by means of PSA values.

To determine the time to treatment failure in both strategies To determine the overall and specific cause survival To evaluate the safety profile To analyze the Quality of Life

Inclusion Criteria:

• Histological or cytological confirmation of prostate adenocarcinoma
• Advanced prostate carcinoma.
• Previous treatment with hormones
• Levels of testosterone < 50 ng/dL
• Good hematological, liver and kidney function
• Previous treatment with surgery or radiotherapy, at least 4 weeks since end of treatment is allowed (the patient should have been recovered from any side effects.

Exclusion Criteria:

• Previous chemotherapy (estramustine included).
• Second line hormonotherapy (oestrogens, gestagens, ketoconazole, ...included)
• Previous treatment with radiotherapy (isotopes) or previous radiotherapy over > 25% of the marrow
• Any malignant process with a free disease interval under 5 years, exception done to non-melanoma skin cancer.
• Concomitant serious diseases
• Concomitant treatment with any other neoplassic therapy (exception done to LHRH agonists and/or biphosphonates).
• Contraindication for the treatment with estramustine.
• Previous history of pulmonary embolism, thromboembolic disease, previous treatment with anticoagulants (except aspirin), active thrombophlebitis or hypercoagulation.
• Previous history of pulmonary spillage or ascitis.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.